Survival Outcomes After Immune-Related Adverse Events in Older Adults With Advanced Non–Small Cell Lung Cancer
Überleben nach immunvermittelten Nebenwirkungen bei älteren Erwachsenen mit fortgeschrittenem nicht-kleinzelligem Lungenkarzinom
Journal of the National Comprehensive Cancer Network · 29.10.2026
DOI: 10.6004/jnccn.2026.7055 ↗Auf einen Blick
Bei 5.304 älteren Patient:innen mit fortgeschrittenem NSCLC unter ICI war ein klinisch bedeutsames irAE mit besserem Gesamtüberleben verbunden. Der Vorteil war ohne Hospitalisierung am größten.
Fragestellung
Sind klinisch bedeutsame immunvermittelte Nebenwirkungen bei älteren Erwachsenen mit fortgeschrittenem NSCLC unter ICI mit dem Gesamtüberleben assoziiert?
Methode
Retrospektive Kohortenstudie mit SEER-Medicare (2010–2019); Patient:innen ≥66 Jahre mit lokal fortgeschrittenem oder metastasiertem NSCLC unter ICI-Monotherapie oder Chemoimmuntherapie 2015–2017; doubly robust causal inference.
Ergebnisse
Kohorte: 5.304 Patient:innen. Klinisch bedeutsame irAE bei 1.807 (34,1 %); medianer Beginn 3,8 Monate. Sterblichkeit: 65,1 % mit irAE vs. 78,7 % ohne irAE; adjustierter absoluter Überlebensvorteil 6,6 % (95 %-KI 5,3–8,0) und 6,5 Monate RMST-Gewinn (95 %-KI 5,6–7,4).
Schlussfolgerung der Autor:innen
Bei älteren Erwachsenen mit fortgeschrittenem NSCLC unter ICIs waren klinisch bedeutsame irAE mit verbessertem Gesamtüberleben verbunden, besonders wenn sie ohne Hospitalisierung behandelt wurden.
Kernaussagen
- Klinisch bedeutsame irAE bei 34,1 % der Patient:innen
- Adjustierter Überlebensvorteil 6,6 % (95 %-KI 5,3–8,0)
- Ohne Hospitalisierung zeigte sich der größte Nutzen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, erschienen am 29.10.2026. Verfasst von Olajumoke A Olateju und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
Background
Immune-related adverse events (irAEs) are common toxicities of immune checkpoint inhibitors (ICIs) in non–small cell lung cancer (NSCLC), but their prognostic implications in older adults remain uncertain. Patients and Methods: We conducted a retrospective cohort study using SEER–Medicare (2010–2019). We included patients aged ≥66 years with locally advanced or metastatic NSCLC who initiated ICI monotherapy or chemoimmunotherapy from 2015–2017. Follow-up began at treatment initiation and continued until death, Medicare disenrollment, or December 31, 2019. The primary exposure was a clinically meaningful irAE, defined as an irAE diagnosis with evidence of systemic immunosuppressant use and/or treatment delay, or discontinuation. In secondary analyses, we categorized patients as having no irAE, an irAE managed without hospitalization, or an irAE requiring hospitalization. The primary outcome was overall survival. We estimated adjusted survival differences and restricted mean survival time using doubly robust causal inference methods.
Results
The cohort included 5,304 patients (mean age, 75 years; 52.7% female; 81.9% White). Clinically meaningful irAEs occurred in 1,807 (34.1%) patients, with a median onset of 3.8 months (IQR, 1.1–9.4). Death occurred in 65.1% of patients with irAEs and 78.7% without irAEs, corresponding to an adjusted absolute survival benefit of 6.6% (95% CI, 5.3%–8.0%) and a 6.5-month gain in restricted mean survival time (95% CI, 5.6–7.4). In secondary analyses, irAEs managed without hospitalization showed the greatest benefit (odds ratio [OR], 0.44; 95% CI, 0.35–0.54), whereas irAE hospitalization was associated with attenuated benefit (OR, 0.94; 95% CI, 0.89–0.99).
Conclusions
Among older adults with advanced NSCLC receiving ICIs, clinically meaningful irAEs were associated with improved overall survival, particularly when managed without hospitalization. These findings highlight the clinical importance of early recognition of immune-related toxicities; irAE-related hospitalization may identify a higher-risk group warranting closer monitoring and supportive care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX.
- 2Department of Medicine, Hematology and Oncology, Baylor College of Medicine, Houston, TX.
- 3Division of Health Outcomes, College of Pharmacy, University of Texas at Austin, Houston, TX.
- 4Division of Outcomes, Research and Quality, Department of Public Health Sciences, Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA.
- 5Department of Pharmacological & Pharmaceutical Sciences, Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX.
Zitieren
APA
Olateju, O. A., Patel, M., Aparasu, R. R., Essien, E. J., Varisco, T. J., Shen, C., Trivedi, M., & Thornton, J. D. (2026). Survival Outcomes After Immune-Related Adverse Events in Older Adults With Advanced Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2026.7055
Vancouver
Olateju OA, Patel M, Aparasu RR, Essien EJ, Varisco TJ, Shen C, et al. Survival Outcomes After Immune-Related Adverse Events in Older Adults With Advanced Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2026.7055
BibTeX
@article{Olateju2026,
author = {Olateju, Olajumoke A and Patel, Meera and Aparasu, Rajender R and Essien, E James and Varisco, Tyler J and Shen, Chan and Trivedi, Meghana and Thornton, J Douglas},
title = {Survival Outcomes After Immune-Related Adverse Events in Older Adults With Advanced Non–Small Cell Lung Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
doi = {10.6004/jnccn.2026.7055}
}
EUVIMED